Embera NeuroTherapeutics and Collaborators Publish Paper in Psychopharmacology Supporting Its Novel Drug Combination, EMB-001, for Smoking Cessation

Embera NeuroTherapeutics Inc., a specialty pharmaceutical company developing novel treatments for smoking cessation and other addictions, announced today the publication of results from a preclinical study of the combination use of metyrapone and oxazepam to treat nicotine addictions. Metyrapone and oxazepam, both of which are FDA-approved drugs, comprise EMB-001, Embera’s lead pipeline candidate. Researchers found that at the lowest doses tested, the combination more effectively reduced nicotine intake than did either drug alone.

Embera NeuroTherapeutics Closes on $4.5 Million Continuation of Series A Financing

Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for smoking cessation and other addictions, announced today that it has closed on $4.5 million in a continuation of its Series A financing. Embera’s existing venture investors, Louisiana Ventures, L.P., Louisiana Fund I, and Themelios Ventures, as well as private investors, participated in the round. Proceeds from this financing, combined with development grant funding from the National Institute for Drug Abuse, will support clinical development of EMB-001 through a Phase 1 safety study, enabling Embera’s clinical development programs for both smoking cessation and cocaine dependence.

Embera NeuroTherapeutics’ Lead Candidate, EMB-001, Supported by $3.9M Grant from National Institute on Drug Abuse

Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for addiction and obesity, announced today that the Louisiana State University Health Sciences Center (LSUHSC-S) has received a $3.9 million dollar grant from the National Institute on Drug Abuse (NIDA). The grant will support the next stages of development for Embera’s drug candidate EMB-001 to treat cocaine dependence, as well as advance EMB-001 into clinical testing. Work done under this grant will also support Embera’s clinical development program for EMB-001 for smoking cessation.